|
| | Publication Year | Title | Author(s) |
| 61 | 6-Jun-2012 | Pulmonary metastases: a rare manifestation of the most common cancer. | Arulananda, Surein; Liew, Mun Sem; Battye, Shane; McDonald, Christine F ; Mitchell, Paul L R |
| 62 | 6-Dec-2011 | Smoking history as a predictive factor of treatment response in advanced non-small-cell lung cancer: a systematic review. | Mitchell, Paul L R ; Mok, Tony; Barraclough, Helen; Strizek, Alena; Lew, Rebecca; van Kooten, Maximiliano |
| 63 | 1-Oct-2011 | Bronchoepidural Fistula in a man with actinomycosis complicated non-small cell lung cancer. | Sem Liew, Mun; Arulananda, Surein; Seow, James; Mitchell, Paul L R ; John, Thomas |
| 64 | 23-May-2011 | Randomized phase 2 sequencing and pharmacokinetic study of gemcitabine and oxaliplatin in advanced non-small cell lung cancer. | Mitchell, Paul L R ; Broad, Adam; Rosenthal, Mark A; Galettis, Peter; Abraham, Rick; Burns, Ivon; Clarke, Stephen; Milner, Alvin; Diiulio, Juliana; Links, Matthew |
| 65 | 24-Dec-2009 | Neurolymphomatosis: diagnosis, management, and outcomes in patients treated with rituximab. | Gan, Hui K ; Azad, Arun A; Cher, Lawrence M ; Mitchell, Paul L R |
| 66 | 17-Nov-2009 | High impact of 18F-FDG-PET on management and prognostic stratification of newly diagnosed small cell lung cancer. | Azad, Arun A; Chionh, Fiona; Scott, Andrew M ; Lee, Szeting T; Berlangieri, Salvatore U ; White, Shane C; Mitchell, Paul L R |
| 67 | 28-Mar-2009 | Prognostic value of 18F-FDG PET/CT in patients with malignant pleural mesothelioma. | Lee, S T; Ghanem, M; Herbertson, R A; Berlangieri, Salvatore U ; Byrne, Amanda J; Tabone, K; Mitchell, Paul L R ; Knight, Simon R ; Feigen, Malcolm; Scott, Andrew M |
| 68 | 1-May-2008 | A phase II study of liposomal daunorubicin, in combination with cyclophosphamide, vincristine and prednisolone, in elderly patients with previously untreated aggressive non-Hodgkin lymphoma. | Mitchell, Paul L R ; Marlton, Paula; Grigg, Andrew P ; Seymour, John F; Hertzberg, Mark; Enno, Arno; Herrmann, Richard; Bond, Rodney; Arthur, Chris |
| 69 | 21-May-2007 | Prevalence of occult metastatic disease in patients undergoing 18F-FDG PET for primary diagnosis or staging of lung carcinoma and solitary pulmonary nodules. | Lee, S T; Berlangieri, Salvatore U ; Poon, A M T; Mitchell, Paul L R ; Pathmaraj, K ; Tabone, K; Byrne, Amanda J; O'Keefe, Graeme J; Knight, Simon R ; Clarke, C Peter; Scott, Andrew M |
| 70 | 1-Jul-2006 | Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity. | Mitchell, Paul L R ; Goldstein, David B; Michael, Michael; Beale, Philip; Friedlander, Michael; Zalcberg, John; White, Shane C; Thomson, Jacquelyn A; Clarke, Stephen |
| 71 | 1-Feb-2006 | Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma. | Loveland, Bruce E; Zhao, Anne; White, Shane C; Gan, Hui K ; Hamilton, Kate ; Xing, Pei-Xiang; Pietersz, Geoffrey A; Apostolopoulos, Vasso; Vaughan, Hilary A; Karanikas, Vaios; Kyriakou, Peter; McKenzie, Ian F C; Mitchell, Paul L R |
| 72 | 19-Nov-2005 | A phase 1 and pharmacokinetic study of gemcitabine and oxaliplatin in patients with solid tumors. | Gan, Hui K ; Mitchell, Paul L R ; Galettis, Peter; Davis, Ian D; Cebon, Jonathan S ; de Souza, Paul; Links, Matthew |
| 73 | 5-May-2005 | Positron emission tomography with selected mediastinoscopy compared to routine mediastinoscopy offers cost and clinical outcome benefits for pre-operative staging of non-small cell lung cancer. | Yap, Kelvin K; Byrne, Amanda J; Berlangieri, Salvatore U ; Poon, Aurora M T ; Mitchell, Paul L R ; Knight, Simon R ; Clarke, Peter C; Harris, Anthony H; Tauro, Andrew; Rowe, Christopher C ; Scott, Andrew M |
| 74 | 1-Jul-2004 | Positron emission tomography scanning in the assessment of patients with lymphoma. | Foo, S S; Mitchell, Paul L R ; Berlangieri, Salvatore U ; Smith, C L; Scott, Andrew M |
| 75 | 17-May-2004 | Austin Bowel Cancer Consortium: changing culture in bowel cancer care. | Mitchell, Paul L R ; White, Craig A |
| 76 | 1-Apr-2004 | A phase II study of escalated-dose docetaxel with granulocyte colony-stimulating factor support in patients with advanced breast cancer. | Mitchell, Paul L R ; Basser, R L; Chipman, M; Grigg, Andrew P ; Mansfield, R; Cebon, Jonathan S ; Davis, Ian D; Appia, F; Green, M |
| 77 | 1-Jul-2003 | Targeting primary human Ph(+) B-cell precursor leukemia-engrafted SCID mice using radiolabeled anti-CD19 monoclonal antibodies. | Mitchell, Paul L R ; Lee, Fook-Thean; Hall, Cathrine; Rigopoulos, Angela; Smyth, Fiona E; Hekman, Anne-Marie; van Schijndel, Gijs M; Powles, Ray; Brechbiel, Martin W; Scott, Andrew M |
| 78 | 1-May-2003 | A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. | Scott, Andrew M ; Wiseman, Greg; Welt, Sydney; Adjei, Alex; Lee, Fook-Thean; Hopkins, Wendie; Divgi, Chaitan R; Hanson, Lorelei H; Mitchell, Paul L R ; Gansen, Denise N; Larson, Steven M; Ingle, James N; Hoffman, Eric W; Tanswell, Paul; Ritter, Gerd; Cohen, Leonard S; Bette, Peter; Arvay, Lisa; Amelsberg, Andree; Vlock, Dan; Rettig, Wolfgang J; Old, Lloyd J |
| 79 | 1-Aug-1999 | KRN8602 (MX2-hydrochloride): an active new agent for the treatment of recurrent high-grade glioma. | Clarke, K; Basser, R L; Underhill, C; Mitchell, Paul L R ; Bartlett, John; Cher, Lawrence M ; Findlay, M; Dalley, D; Pell, M; Byrne, M; Geldard, H; Hill, J S; Maher, D; Fox, R M; Green, M D; Kaye, A H |
Loading...
2
0
20
0
false